Alina Arulsamy

Dr. Alina Arulsamy

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2020 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
AAAlina Arulsamy
Alina Arulsamy
QTQian Ying Tan
Qian Ying Tan
VBVinod Balasubramaniam
Vinod Balasubramaniam
TOTerence J. O’brien
Terence J. O’brien
MSMohamad F Shaikh
Mohamad F Shaikh

16 July 2024 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
EAEnes Akyuz
Enes Akyuz
AAAlina Arulsamy
Alina Arulsamy
FAFeyza Sule Aslan
Feyza Sule Aslan
BSBugra Sarisözen
Bugra Sarisözen
BGBeyzanur Guney
Beyzanur Guney
MSMohamad F Shaikh
Mohamad F Shaikh
Alzheimer’s disease (AD) is a progressive neurodegenerative disease. The accumulation of amyloid-β (Aβ) plaques and tau neurofibrillary tangles are the key players responsible for the pathogenesis of the disease. The accumulation of Aβ plaques and tau affect the balance in chemical neurotransmitters in the brain. Thus, the current review examined the role of neurotransmitters in the pathogenesis of Alzheimer’s disease and discusses the alterations in the neurochemical activity and cross talk with their receptors and transporters. In the presence of Aβ plaques and neurofibrillary tangles, changes may occur in the expression of neuronal receptors which in turn triggers excessive release of glutamate into the synaptic cleft contributing to cell death and neuronal damage. The GABAergic system may also be affected by AD pathology in a similar way. In addition, decreased receptors in the cholinergic system and dysfunction in the dopamine neurotransmission of AD pathology may also contribute to the damage to cognitive function. Moreover, the presence of deficiencies in noradrenergic neurons within the locus coeruleus in AD suggests that noradrenergic stimulation could be useful in addressing its pathophysiology. The regulation of melatonin, known for its effectiveness in enhancing cognitive function and preventing Aβ accumulation, along with the involvement of the serotonergic system and histaminergic system in cognition and memory, becomes remarkable for promoting neurotransmission in AD. Additionally, nitric oxide and adenosine-based therapeutic approaches play a protective role in AD by preventing neuroinflammation. Overall, neurotransmitter-based therapeutic strategies emerge as pivotal for addressing neurotransmitter homeostasis and neurotransmission in the context of AD. This review discussed the potential for neurotransmitter-based drugs to be effective in slowing and correcting the neurodegenerative processes in AD by targeting the neurochemical imbalance in the brain. Therefore, neurotransmitter-based drugs could serve as a future therapeutic strategy to tackle AD.

22 June 2022 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
ZDZüleyha Doğanyiğit
Züleyha Doğanyiğit
KEKaan Erbakan
Kaan Erbakan
Enes AkyuzEnes Akyuz
Enes Akyuz
APAyse Kristina Polat
Ayse Kristina Polat
AAAlina Arulsamy
Alina Arulsamy
MSMohamad F Shaikh
Mohamad F Shaikh

1 August 2017 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
FCFrances Corrigan
Frances Corrigan
AAAlina Arulsamy
Alina Arulsamy
LCLyndsey E Collins-Praino
Lyndsey E Collins-Praino
JHJoshua L. Holmes
Joshua L. Holmes
RVRobert Vink
Robert Vink

1 January 2018 in Behavioural Brain Research
Verified
Journal Article
Closed access
LCLyndsey E Collins-Praino
Lyndsey E Collins-Praino
AAAlina Arulsamy
Alina Arulsamy
VKViythia Katharesan
Viythia Katharesan
FCFrances Corrigan
Frances Corrigan

1 August 2018 in Behavioural Brain Research
Verified
Journal Article
Closed access
AAAlina Arulsamy
Alina Arulsamy
JTJason Teng
Jason Teng
HCHolly Colton
Holly Colton
FCFrances Corrigan
Frances Corrigan
LCLyndsey E Collins-Praino
Lyndsey E Collins-Praino